Clinical study of antiviral treatment combined with transcatheter arterial chemoemholization (TACE) in patients with hepatitis B cirrhosis complicated hepatocellular carcinoma

Objective To investigate the effects of antiviral treatment combined with transcatheter arterial chemoemholization (TACE) in patients with hepatitis B cirrhosis complicated hepatocellular carcinoma (HCC) .Methods Retrospectively analyzed the effects of antiviral treatment combined with TACE in 78 cases with Hepatitis B cirrhosis complicated HCC, and compared with 81 patients that separately used TACE at the same time.One or two years′ survival rate, Child-Pugh score and HBV DNA were measured.There were no significant differences between two groups in basic clinical materials (P>0.05) (include sex, age, tumor size, laboratory examination and Child-Pugh score) .Results After one or two years′ treatment, the conversion rates of HBV DNA of treatment group were significantly higher than those of the control group (P<0.0001) , Child-Pugh scores of treatment group were significantly lower than those of the control group (P<0.001) , the differences were significantly.The one or two years′ survival rates of treatment group were 83.33% and 66.67%, while control group were 59.2% and 36.67% (P<0.001) , the differences were significantly.Conclusion Nucleoside analogues combined with TACE, can reduce the level of HBV DNA, protect liver functions and increase survival rates considerably in patients with hepatitis B cirrhosis complicated HCC.